BioMarin Pharmaceutical 3Q 2026: Revenue $1.02B, Net loss $122.8M, EPS $(0.63) — 10-Q Summary

What happened

BioMarin Pharmaceutical reported third-quarter 2026 revenue of $1.02 billion, up 32% from $776.1 million a year earlier. Its net loss widened to $122.8 million from $30.7 million, and diluted loss per share increased to $0.63 from $0.16.

Confirmed

Global impact / market context

Revenue rose sharply, partly because acquired GALAFOLD and POMBILITI plus OPFOLDA added $336.4 million over nine months. Yet the net loss widened, so investors must judge whether the Amicus acquisition and higher acquired-product amortization, which means spreading recorded asset costs over time, can eventually turn growth into profit.

Analyst inference

The company is adding marketed therapies through the Amicus acquisition while spending on a $70 million BMN 450 license payment in the fourth quarter. It also awaits FDA decisions on VOXZOGO in achondroplasia and hypochondroplasia, so sales growth, acquisition costs, and regulatory outcomes drive the investment case.

Analyst inference

What to watch

1. The FDA accepted VOXZOGO applications for full approval in achondroplasia and for hypochondroplasia, with decisions targeted for February and May 2027, which could expand the drug's approved uses. Confirmed
2. BioMarin plans a $70 million BMN 450 license payment in the fourth quarter of 2026 and expects acquired-product amortization to increase, which will weigh on reported costs. Confirmed
3. Watch whether VOXZOGO patient uptake, mainly international, plus PALYNZIQ and VIMIZIM growth offsets declining NAGLAZYME revenue and whether wider losses persist after the Amicus deal. Analyst inference

Evidence

• Original source link unavailable